Evidence
- igarashi_2022_rct_galcanezumab-effects-on-migraine-severity-and-symptoms-in-japanese-patients-with-episodic-migraine
- igarashi_2022_rct_galcanezumab-effects-on-migraine-severity-and-symptoms-in-japanese-patients-with-episodic-migraine
- igarashi-h_2023_rct_galcanezumab-effects-on-migraine-severity-and-symptoms-in-japanese-patients-with-episodic-migraine-secondary-analysis-of-a-phase-2-randomized-trial
- igarashi-h_2023_rct_galcanezumab-effects-on-migraine-severity-and-symptoms-in-japanese-patients-with-episodic-migraine-secondary-analysis-of-a-phase-2-randomized-trial